| Dr Rohan R Arya, MD | |
|
2728 Sunset Blvd Ste 104, West Columbia, SC 29169-4838 | |
| (803) 256-0464 | |
| (803) 254-5121 |
| Full Name | Dr Rohan R Arya |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 16 Years |
| Location | 2728 Sunset Blvd Ste 104, West Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093950602 | NPI | - | NPPES |
| 383720 | Medicaid | SC |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prisma Health Richland Hospital | Columbia, SC | Hospital |
| Lexington Medical Center | West columbia, SC | Hospital |
| Prisma Health Baptist | Columbia, SC | Hospital |
| Prisma Health Baptist Parkridge | Columbia, SC | Hospital |
| Prisma Heath Tuomey Hospital | Sumter, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lexington Health Inc | 2567872070 | 753 |
| Prisma Health Medical Group-midlands | 5991099707 | 865 |
News Archive
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.
Elan Corporation, plc announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"),
For women with type 1 diabetes, monitoring blood sugar levels continuously during pregnancy via an implanted device helps better manage the disease, and improves birth outcomes compared to traditional finger-prick tests, according to a new randomized trial published in The Lancet and presented at the European Association for the Study of Diabetes conference.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that positive microplasmin Phase II trial results, evaluating the product for the nonsurgical treatment of vitreomacular adhesion, have been published in the July/August issue of the journal Retina.
› Verified 9 days ago
| Entity Name | Prisma Health Medical Group-midlands |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275988321 PECOS PAC ID: 5991099707 Enrollment ID: O20160802001226 |
News Archive
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.
Elan Corporation, plc announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"),
For women with type 1 diabetes, monitoring blood sugar levels continuously during pregnancy via an implanted device helps better manage the disease, and improves birth outcomes compared to traditional finger-prick tests, according to a new randomized trial published in The Lancet and presented at the European Association for the Study of Diabetes conference.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that positive microplasmin Phase II trial results, evaluating the product for the nonsurgical treatment of vitreomacular adhesion, have been published in the July/August issue of the journal Retina.
› Verified 9 days ago
| Entity Name | Lexington Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710634753 PECOS PAC ID: 2567872070 Enrollment ID: O20201208000922 |
News Archive
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.
Elan Corporation, plc announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"),
For women with type 1 diabetes, monitoring blood sugar levels continuously during pregnancy via an implanted device helps better manage the disease, and improves birth outcomes compared to traditional finger-prick tests, according to a new randomized trial published in The Lancet and presented at the European Association for the Study of Diabetes conference.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that positive microplasmin Phase II trial results, evaluating the product for the nonsurgical treatment of vitreomacular adhesion, have been published in the July/August issue of the journal Retina.
› Verified 9 days ago
| Entity Name | Inspire Pulmonary |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922772904 PECOS PAC ID: 9931507183 Enrollment ID: O20211001002461 |
News Archive
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.
Elan Corporation, plc announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"),
For women with type 1 diabetes, monitoring blood sugar levels continuously during pregnancy via an implanted device helps better manage the disease, and improves birth outcomes compared to traditional finger-prick tests, according to a new randomized trial published in The Lancet and presented at the European Association for the Study of Diabetes conference.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that positive microplasmin Phase II trial results, evaluating the product for the nonsurgical treatment of vitreomacular adhesion, have been published in the July/August issue of the journal Retina.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rohan R Arya, MD Po Box 6069, West Columbia, SC 29171-6069 Ph: (803) 256-0464 | Dr Rohan R Arya, MD 2728 Sunset Blvd Ste 104, West Columbia, SC 29169-4838 Ph: (803) 256-0464 |
News Archive
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.
Elan Corporation, plc announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"),
For women with type 1 diabetes, monitoring blood sugar levels continuously during pregnancy via an implanted device helps better manage the disease, and improves birth outcomes compared to traditional finger-prick tests, according to a new randomized trial published in The Lancet and presented at the European Association for the Study of Diabetes conference.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that positive microplasmin Phase II trial results, evaluating the product for the nonsurgical treatment of vitreomacular adhesion, have been published in the July/August issue of the journal Retina.
› Verified 9 days ago
Dr. Robert Anthony Leonardi, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2728 Sunset Blvd Ste 300, West Columbia, SC 29169 Phone: 803-744-4940 Fax: 803-744-4938 | |
Dr. Vijaya Korrapati, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 E Medical Ln Ste 400, West Columbia, SC 29169 Phone: 803-794-7511 Fax: 803-794-7751 | |
Parthivkumar N Kundaria, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2480 Fax: 803-936-4102 | |
Jonathan Kyle Hewett, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2728 Sunset Blvd Ste 300, West Columbia, SC 29169 Phone: 803-744-4940 Fax: 803-744-4938 | |
Dr. Carl A White, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 146 N Hospital Drive, Suite 530, West Columbia, SC 29169 Phone: 803-796-7270 Fax: 803-796-0106 | |
Perrie L Ryan, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 E Medical Ln Ste 400, West Columbia, SC 29169 Phone: 803-794-7511 Fax: 803-794-7751 | |
Dr. Christopher Patrick Rowley, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2728 Sunset Blvd Ste 300, West Columbia, SC 29169 Phone: 803-744-4940 Fax: 803-744-4938 |